MFN Cuts Manufacturer Prices, But Savings Still Face A Longer Journey

The federal government’s Most-Favored-Nation (MFN) drug pricing initiative promises billions in potential savings, but will those lower manufacturer prices actually reach employers, health plans, and patients? In his latest article, Paul Pruitt, Chief Growth Officer at SHARx, breaks down the complex supply chain economics and challenges surrounding real pharmacy cost containment.

As Pruitt states: “Lowering the manufacturer price is a meaningful starting point. The real measure of success is being able to demonstrate where the savings went and who ultimately benefited.”